The Biggest Biotech Wins of the Week

While most industry analysts had their hands full with recently released ASCO abstracts, a handful of clinical wins flew largely under the radar. The catastrophe that nearly cut Halozyme Therapeutics' (NASDAQ: HALO  ) market cap in half might reverse somewhat. Loss mitigation aside, the biggest winners were in diabetes. It looks like Eli Lilly (NYSE: LLY  ) might have a leg up in the growing market for long-lasting insulin. Outright innovation earned biggest win for Isis Pharmaceuticals (NASDAQ: ISIS  ) and its novel approach to treating type 2 diabetes.

A second chance
First up is Halozyme, with more of a save than an actual win. This company found a safety net near the bottom of a freefall that began last month. It began April with a major catastrophe when a data monitoring committee (DMC) recommended stopping a pancreatic cancer trial with its candidate PEGPH20.

After some consideration from the DMC, the company's future is looking much brighter. When Halozyme reported earnings last Monday, it included a positive statement regarding the ill-fated trial. The DMC has considered Halozyme's amended protocol and now supports continued enrollment of patients. It's an important step, but the trial is still under a clinical hold placed by the FDA, so let's not get too confident yet.

HALO Chart

HALO data by YCharts

Keep your eyes open for an announcement from the agency. The company's stock barely moved in response to the DMC reconsideration. If the FDA eventually lifts the hold, investors might regain some of what was lost following the initial halt.

Once-daily insulin contender
Runner-up for the biggest win of the week goes to Eli Lilly. Last Monday, the beleaguered drug major earned some bragging rights for its basal insulin treatment. In three head-to-head trials, peglispro was more efficacious than Sanofi's (NYSE: SNY  ) Lantus at reducing blood glucose levels for type 2 diabetes patients. In addition to controlling blood glucose, weight gain reductions among peglispro patients was icing on the cake.

LLY Revenue (TTM) Chart

LLY Revenue (TTM) data by YCharts

After a couple years years of sinking revenues, Eli Lilly badly needs a big win. Sanofi booked nearly $2 billion in first quarter Lantus sales and growth is strong. Taking a significant share of the long lasting insulin market could help Lilly return to growth. With these results in hand, peglispro may have a decent chance. There is one potential issue that may rain on the parade -- in the trial, an increase in liver enzymes (a potential -- emphasis on potential -- sign of liver toxicity) was noted in patients, so stay tuned for more data. Of course, Lilly needs to win an approval for the once-daily diabetes treatment first before we can really talk commercialization. Don't hold your breath, as the company doesn't plan to file with U.S. or EU regulators until early next year.

Something different
While Eli Lilly was making incremental advances with insulin, Isis Pharmaceuticals' unique angle of attack earned it the biggest clinical win of the week. Shares of the RNA antisense pioneer popped Wednesday morning after announcing positive results from a 75-patient mid-stage trial with ISIS-GCGR in type 2 diabetes patients.

ISIS Chart

ISIS data by YCharts

The winning candidate is supposed to control blood sugar by limiting the effects of glucagon, a hormone that opposes the action of insulin. Uncontrolled secretion of glucagon becomes increasingly common in type 2 diabetes patients as their disease progresses.

Curtailing the expression of glucagon receptors should be an effective method for controlling blood sugar in advanced patients, but as a first-in-class therapy there are plenty of unknowns. If there is one symptom that could bring the program crashing down, it's signs of liver damage. Patients receiving ISIS-GCGR showed liver enzyme elevations consistent with the pharmacology of glucagon receptor inhibition. The elevations were not associated with typical indicators of liver damage, but regulators are typically hypersensitive about safety issues with new diabetes therapies. Isis intends to break out more details at the annual meeting of the American Diabetes Association in mid-June. Investors will want to watch out for further signs of safety issues during the presentation.

Looking for big winners? How about Warren Buffett's latest pick?
Imagine a company that rents a very specific and valuable piece of machinery for $41,000... per hour (that's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2965726, ~/Articles/ArticleHandler.aspx, 8/30/2015 8:14:22 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Cory Renauer

Cory is a long-term minded analyst mainly focused on the biotechnology and pharmaceuticals. He genuinely enjoys cutting through the industry's complexities to help everyday investors make better decisions. You can contact Cory on Twitter @coryrenauer

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
HALO $18.41 Up +0.37 +2.05%
Halozyme Therapeut… CAPS Rating: ****
ISIS $51.54 Down -0.02 -0.04%
Isis Pharmaceutica… CAPS Rating: *****
LLY $83.19 Down -0.55 -0.66%
Eli Lilly & Co. CAPS Rating: ****
SNY $49.28 Down -0.80 -1.60%
Sanofi (ADR) CAPS Rating: *****